Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
IBI355 MAD Study in Healthy Volunteers
NCT06416787Phase 1Completed
- Sponsor
- Innovent Biologics
- Start
- May 2024
- Primary completion
- Feb 2025
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial of IBI-355 in primary Sjögren's syndrome and systemic lupus erythematosus (SLE) (4 arms), sponsored by Innovent Biologics. Primary endpoint: Incidence of adverse events and serious adverse events. Started May 2024; status: completed.
02
Drugs
IBI-355
03
Conditions
primary Sjögren's syndromesystemic lupus erythematosus (SLE)
Beyond the preview
Go deeper on NCT06416787.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06416787.